The Advantages Of A Web-Based System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Advantages Of A Web-Based System
Dr. Fred Jordan, CEO at AlpVision SA, explains how web-based server solutions can aid anticounterfeiting strategies and why such systems are seeing increased uptake.


Pharmaceutical Technology Europe
Volume 23, Issue 11

There are two fundamental ways that web-based servers can be used to assist anticounterfeiting strategies.


Fred Jordan. CEO at AlpVision SA.
The first approach involves using the server as a data repository system; for example, to see what different anticounterfeiting features have been deployed (holograms, inks, labels, covert invisible inks etc.) for a given packaging number, to look up serial numbers (although this has limited efficiency for authentication purposes) or to display what the package should look like. This information can be used systems such as the Interface Public Member of the World Customs Organization, or the Drug Validation Portal (1,2), which enable customs to check whether a pharmaceutical shipment is counterfeit.

The second approach entails uses the server to analyse different packaging parameters to assess authenticity automatically. For instance, solutions are available that can process a picture of a packaging component (e.g., folding box, blister pack, label, flip-off top or part of a vial) and detect whether it is authentic. Our Krypsos system uses the image to determine whether the product is protected by one of our other technologies. If so, the information retrieved is displayed for logged users to see.

Industry uptake

Uptake of any technology in the pharma industry takes time and this is also true of web-based servers, which also present additional challenges in terms of security concerns. Such systems must run software compliant with a number of standards, including CSV (Computer Software Validation), GAMP 4/5 and FDA 11–21, to cite the most prominent ones. However, based on our experience, many companies implement a web-based server because of versatility (by offering both a database and authentication) and ubiquity (works from anywhere in the world).

Before rolling out a new web-based anticounterfeiting system, companies need to consider numerous points. Firstly, does the system require CSV? If so, price and development times substantially increase. Companies must also ask: What is the purpose of the server (database and/or authentication)? Is there an actual need for a centralised authentication server? Sometimes, the major reason for the server to exist is that it avoids software installation on every computer, thus simplifying deployment, preserving security and enabling audit trails. If there is a need for this kind of server, then what exactly needs to be centralised?

The server logic must precisely match and integrate with many processes of the pharma company (relations with suppliers, production, QA, orders, etc) and it must at the same time implement new processes (how to authenticate, when, how, by whom, etc). It is critical to define precisely such processes. This can be done either iteratively by starting with a simple system and evolving it progressively, or by directly implementing a system matching user requirement specifications derived from the processes. The second approach is more tuned to CSV developments too.

Overall, I believe that a web-based server strategy is an appropriate approach for companies who require global access to an authentication platform. It provides for centralised management and worldwide statistics of authentication information, with the benefit of easy global deployment.

References

1.Public Member Interface http://ipmpromo.wcoomdpublications.org

2. Drug Validation Portal http://www.dvp-eu.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here